Boehringer Ingelheim’s BI 690517 reduces albuminuria in Phase 2 CKD trial
The Phase 2 trial assessed BI 690517 on top of empagliflozin against placebo for 14 weeks and the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Nov 23
The Phase 2 trial assessed BI 690517 on top of empagliflozin against placebo for 14 weeks and the…
06 Nov 23
The results showed statistically significant and clinically meaningful reductions in UACR, used to assess albuminuria, at 12 weeks…
06 Nov 23
The results were consistent across every month and every-other-month dosing of Izervay against sham through two years of…
03 Nov 23
The reduction in systolic blood pressure during treatment in the Phase 4 trial was more significant at Week…
02 Nov 23
The anti-PD-1 therapy delivered a statistically significant improvement in OS as an adjuvant treatment in RCC patients at…
31 Oct 23
The programmed death receptor-1 (PD-1)-blocking antibody showed a statistically significant and clinically meaningful benefit in the overall patient…
31 Oct 23
The drug candidate met the primary efficacy endpoint by showing a clinically meaningful and highly statistically significant proteinuria…
27 Oct 23
The study assessed the safety, tolerability, and immunogenicity of the combination vaccine candidates against a licensed influenza vaccine…
26 Oct 23
Arexvy met the Phase 3 trial’s primary endpoints by eliciting an immune response that was non-inferior to that…
26 Oct 23
The Japanese company compared data from earlier trials involving 898 patients who received Leqembi by infusion to data…